Braftovi
Chemical Name | encorafenib |
Dosage Form | Capsule (oral; 75 mg) |
Drug Class | Kinase inhibitors |
System | Skin |
Company | Array Biopharma |
Approval Year | 2018 |
Indication
- Braftovi is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.